Aehr Test Systems (AEHR) Q4 2026 Earnings Call Transcript

Aehr Test Systems reported Q4 revenue of $18.8M (+34% YoY) and non-GAAP EPS of $0.11 vs a loss of $0.01, driven by AI and data center demand. Bookings surged to $60.7M (+500%) and effective backlog rose to $100.6M, while non-GAAP gross margin increased 1,000 bps to 45%. Management guided FY2027 revenue to $130M–$150M (160%–200% growth) with non-GAAP pretax net income margin of 18%–22%, alongside $100M raised via an at-the-market equity offering to support scaling. Overall, results and guidance suggest a strong inflection, though the company flagged supply-chain price increases (notably ~40%) and ongoing China patent litigation costs.

Analysis

The setup is less about a one-quarter beat and more about whether AEHR can convert a narrow customer set into a repeatable consumables annuity. The real beneficiaries are AI accelerator and silicon-photonics OEMs that can shift failure screening left into wafer-level test: that lowers field-failure risk and should improve system-level yields, but it also compresses the value capture of downstream package-test workflows. If this adoption broadens, the incremental margin pool migrates toward niche, IP-heavy test architectures rather than commodity ATE, which is why the market may start underwriting a higher terminal multiple if shipment cadence holds.

The near-term risk is execution, not demand. This is a classic “bookings first, revenue later” story with a concentrated customer base, supply-chain inflation, and inherently lumpy install timing; the stock can gap on guide, but the next 1-2 quarters will be judged on conversion, not rhetoric. Falsifiers: backlog slipping below the current implied run-rate, gross margin reverting under the low-40s due to component cost inflation, or any sign that the big AI accounts are only evaluating wafer-level burn-in rather than committing to production.

Contrarian take: consensus is probably overstating how much of the fiscal 2027 guide is durable and underestimating how much is already embedded in current sentiment. The market may be pricing a multi-year AI test supercycle, but AEHR still depends on a handful of large programs and on customers accepting a process change that can be delayed by qualification, foundry allocation, or packaging redesigns. If memory/HBM doesn’t turn into contracted revenue, the structural upside is real but less immediate than bulls are assuming.

Key Decisions for Investors

• Long AEHR only on pullbacks after the earnings gap, using a starter position and adding on evidence that Q1/Q2 shipments are converting backlog; thesis is 12-18 months, but first test is the next quarter’s book-to-bill and gross margin.
• Buy AEHR Jan-2027 call spreads instead of common for upside participation with defined risk; target a 2:1 to 3:1 payoff if the company proves it can sustain >$140M revenue and >40% gross margin.
• Pair trade: long AEHR / short TER as a relative play on wafer-level burn-in share gains versus broader semi-test, but keep sizing modest because AEHR is still customer-concentrated and TER is only an indirect loser.
• Set a hard thesis watchpoint: if revenue guidance is not reaffirmed or raised on the next call, or gross margin slips below 42%, reduce exposure; that would suggest the current move is more narrative than durable earnings power.
• Watch NVDA and AI capex proxies (NVDA, GOOGL, META) for a slowdown in accelerator/optics buildouts; a capex reset would hit AEHR’s 1-2 quarter order visibility faster than it hits the broader semi equipment group.